How Ovarian Cancer Stage Determines Treatment
\n\n\nWhen a patient is referred to me with suspected ovarian cancer, the first clinical question is staging: how far has the disease spread? The FIGO staging system classifies ovarian cancer from Stage I (confined to one or both ovaries) to Stage IV (spread beyond the abdomen). This staging determines not just prognosis but the entire treatment architecture.
\n\n\nPrimary Cytoreductive Surgery
\n\n\nFor most patients with ovarian cancer, the cornerstone of treatment is cytoreductive surgery (also called debulking surgery). The goal is to remove as much tumour burden as possible, ideally leaving no visible residual disease (R0 resection). Achieving complete cytoreduction is the single most important prognostic factor in advanced ovarian cancer.
\n\n\nA complete cytoreduction for advanced-stage disease typically involves:
\n\n\n- \n
- Total hysterectomy with bilateral salpingo-oophorectomy \n
- Omentectomy (removal of the fatty apron covering the bowel) \n
- Pelvic and para-aortic lymph node dissection (in selected cases) \n
- Removal of all peritoneal deposits visible to the naked eye \n
- En-bloc resection of the rectum or bowel if involved \n
- Diaphragm stripping if disease has spread to its undersurface \n
This is complex, multi-visceral surgery that requires training beyond standard gynaecology. It is best performed by a subspecialist gynaecological oncologist at a centre with multidisciplinary oncology support.
\n\n\nNeoadjuvant Chemotherapy and Interval Debulking
\n\n\nWhen tumour burden is very high or the patient is medically frail, neoadjuvant chemotherapy (3 cycles of carboplatin and paclitaxel before surgery) may be given to shrink the disease, followed by interval debulking surgery and 3 further cycles. This approach achieves comparable survival outcomes to upfront surgery in carefully selected patients.
\n\n\nHIPEC: Heated Intraperitoneal Chemotherapy
\n\n\nHIPEC is a technique in which chemotherapy solution is heated to 40–42°C and circulated directly within the abdominal cavity at the time of surgery. The heat increases drug penetration into residual microscopic cancer cells while limiting systemic exposure.
\n\n\nThe OVHIPEC-1 trial (New England Journal of Medicine, 2018) demonstrated a significant survival benefit for HIPEC added to interval debulking surgery in Stage III ovarian cancer. At our centre in Ahmedabad, HIPEC is offered as part of a comprehensive treatment pathway for selected patients with peritoneal disease.
\n\n\nTargeted Therapy: PARP Inhibitors
\n\n\nPatients with BRCA1/BRCA2 mutations or homologous recombination deficiency now benefit from PARP inhibitor maintenance therapy (olaparib, niraparib) after completing primary chemotherapy. These oral tablets have transformed the maintenance landscape for ovarian cancer, converting what was once a uniformly fatal Stage III diagnosis into a manageable chronic disease for many patients.
\n\n\nGenetic counselling and BRCA testing is recommended for all women with a new ovarian cancer diagnosis — not just for their own treatment planning, but for the screening implications for first-degree relatives.
\n\n\nFor a personalised consultation about ovarian cancer treatment options in Ahmedabad, contact Dr. Nishtha Tripathi Patel at +91 76988 00333.
\n\n\n\n\n\n\n